Sihua Liu, Beidi Du, Shuling Zhou, Nan Shao, Shaoquan Zheng, Xiaying Kuang, Yunjian Zhang, Yawei Shi, Ying Lin
{"title":"Patterns of Recurrence and Survival Outcomes of HER2-Low Expression in Early-Stage Breast Cancer.","authors":"Sihua Liu, Beidi Du, Shuling Zhou, Nan Shao, Shaoquan Zheng, Xiaying Kuang, Yunjian Zhang, Yawei Shi, Ying Lin","doi":"10.1016/j.clbc.2024.11.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To characterize site-specific recurrence patterns and survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer.</p><p><strong>Methods: </strong>This retrospective cohort study included patients diagnosed with early-stage breast cancer at a single institution in China from January 2010 to December 2020. Patterns of the first site of recurrence were compared between patients with HER2-low and HER2-0 tumors using competing risks regression analysis. Disease-free survival (DFS) and overall survival (OS) were evaluated using Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 2055 patients were analyzed (median follow-up 52.3 months), comprising 1102 (53.6%) patients with HER2-low and 953 (46.4%) with HER2-0 tumors. Patients with HER2-0 tumors had a significantly higher 5-year cumulative incidence of visceral recurrence than those with HER2-low tumors (7.20% vs. 4.50%; P = .046), especially for the lung recurrence (4.16% vs. 2.81%; P = .044). In the hormone receptor (HoR)-positive subgroup, HER2-low patients had a significantly higher risk of local recurrence (10-year cumulative incidence rate, 7.58% vs. 2.61%; P = .013) but a relatively lower risk of contralateral breast cancer (10-year cumulative incidence rate, 0.90% vs. 4.53%; P = .044) compared with HER2-0 patients. Nevertheless, there were no significant differences between the HER2-0 and HER2-low patients regarding the time to all sites of recurrence after adjusting other potential risk factors (all P > .05), DFS (P = .763), and OS (P = .106).</p><p><strong>Conclusion: </strong>Site-specific recurrence patterns differ between HER2-low and HER2-0 patients. However, it does not support that HER2-low breast cancer is a distinct prognostic subtype.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2024.11.016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To characterize site-specific recurrence patterns and survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer.
Methods: This retrospective cohort study included patients diagnosed with early-stage breast cancer at a single institution in China from January 2010 to December 2020. Patterns of the first site of recurrence were compared between patients with HER2-low and HER2-0 tumors using competing risks regression analysis. Disease-free survival (DFS) and overall survival (OS) were evaluated using Kaplan-Meier method.
Results: A total of 2055 patients were analyzed (median follow-up 52.3 months), comprising 1102 (53.6%) patients with HER2-low and 953 (46.4%) with HER2-0 tumors. Patients with HER2-0 tumors had a significantly higher 5-year cumulative incidence of visceral recurrence than those with HER2-low tumors (7.20% vs. 4.50%; P = .046), especially for the lung recurrence (4.16% vs. 2.81%; P = .044). In the hormone receptor (HoR)-positive subgroup, HER2-low patients had a significantly higher risk of local recurrence (10-year cumulative incidence rate, 7.58% vs. 2.61%; P = .013) but a relatively lower risk of contralateral breast cancer (10-year cumulative incidence rate, 0.90% vs. 4.53%; P = .044) compared with HER2-0 patients. Nevertheless, there were no significant differences between the HER2-0 and HER2-low patients regarding the time to all sites of recurrence after adjusting other potential risk factors (all P > .05), DFS (P = .763), and OS (P = .106).
Conclusion: Site-specific recurrence patterns differ between HER2-low and HER2-0 patients. However, it does not support that HER2-low breast cancer is a distinct prognostic subtype.
期刊介绍:
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.